SLFN11 expression was found to be correlated to PARP inhibitor response, especially talazoparib, in the NCI-60 panel of human cancer cell lines and was experimentally shown to sensitize cancer cells to PARP inhibitors including olaparib [21]. The gene discussed is PARP1; the disease is cancer.